INTRODUCTION
============

The cystic fibrosis transmembrane conductance regulator (*CFTR*) gene is located at chromosome 7q31.2, where it is flanked upstream by *ASZ1* (ankyrin repeat, SAM and basic leucine zipper) and downstream by *CTTNBP2* (cortactin binding protein 2). These neighbouring genes have very different expression profiles: *CFTR* is expressed primarily in specialized epithelial cells ([@B1; @B2; @B3]), while *ASZ1* is transcribed exclusively in the testis and ovary ([@B4]), and *CTTNBP2* is highly expressed in the brain, kidney and pancreas, with lower levels of expression in other tissues ([@B5]). We previously identified two enhancer-blocking insulators 5′ and 3′ to the *CFTR* gene that had distinct properties. First, a DNase I hypersensitive site (DHS) located at −20.9 kb with respect to the translation start site was associated with a classical CTCF-dependent insulator element ([@B6]). CTCF, a ubiquitously expressed, zinc finger DNA-binding protein ([@B7],[@B8]) often establishes independently regulated domains of gene activity. A second element, located 3′ to *CFTR*, within a DHS at +15.6 kb also demonstrated enhancer-blocking activity but this was independent of CTCF-binding. The +15.6 kb DHS was marked by a peak of euchromatin-specific histone modifications, unlike the −20.9 kb DHS ([@B6]), supporting the hypothesis that these elements function by different mechanisms.

*CFTR* exhibits tightly regulated expression, both temporally during development, and spatially in different tissue types ([@B1],[@B9],[@B10]). However, somewhat paradoxically, the *CFTR* promoter resembles that of a house-keeping gene, in that it is CpG rich, contains no TATA box, has multiple transcription start sites and has several putative binding sites for the transcription factor Sp1 ([@B11]). Consistent with promoters of this type, the *CFTR* promoter demonstrates no apparent tissue-specificity, suggesting the involvement of distal regulatory elements in control of *CFTR* expression. It is probable that these elements are associated with DHS across 400 kb encompassing the *CFTR* locus ([@B12; @B13; @B14; @B15]). In addition to the prominent site at +15.6 kb other DHS were evident 3′ to the coding region of the gene, in particular, a complex cluster of sites at +5.4 kb, +6.8 kb, +7.0 kb and +7.4 kb from the *CFTR* translation end-point ([@B13]). The DHS at +5.4 kb and +7.0 kb were observed in a variety of cell types, irrespective of *CFTR* expression; however, the DHS at +6.8 kb and +7.4 kb were only found in a restricted number of *CFTR*-expressing cell-types, including primary epididymis cells, suggesting that they may contain tissue-specific regulatory elements that participate in controlling *CFTR*-expression ([@B13]).

Here we demonstrate that the +6.8 kb DHS is associated with a tissue-specific CTCF-binding site that displays enhancer-blocking activity comparable to that of other known insulator elements, including the one at the *CFTR* −20.9 kb DHS. CTCF is thought to be involved in regulating nuclear organisation and CTCF-dependent chromatin loops exist ([@B16; @B17; @B18]), which may depend on tethering to the nuclear matrix ([@B19],[@B20]) and/or association with cohesins ([@B21; @B22; @B23]). Hence, we next evaluated the three-dimensional structure of the *CFTR* locus in primary cells that exhibit the +6.8 kb DHS and express *CFTR*. Using chromosome conformation capture (3C), we demonstrate that a region encompassing the +6.8 kb DHS shows strong interaction with the *CFTR* promoter in these cells. We predict that looping of *CFTR*, possibly induced by CTCF, enables key regulatory elements at the 3′-end of the gene to move into close proximity with the *CFTR* promoter, so activating cell-type-specific expression.

MATERIALS AND METHODS
=====================

Cell culture
------------

The K562 erythroleukemia cell line ([@B24]) was cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS). The Caco2 ([@B25]) cell line was cultured in DMEM supplemented with 10% FCS. Primary human fetal male epididymis cells ([@B26]) were cultured in CMRL1066 medium, 15% FCS, supplemented with hydrocortisone, insulin and cholera toxin. Human skin fibroblasts (GM08333) were cultured in MEM medium with 15% FCS.

Chromatin immunoprecipitation
-----------------------------

Chromatin immunoprecipitation (ChIP) was carried out following the Upstate protocol with minor modifications. Briefly, 5 × 10^7^ cells were crosslinked with 1% formaldehyde for 10 min at room temperature. Crosslinking was stopped by the addition of Glycine to 0.125 M. Cells were washed in cold phosphate-buffered saline (PBS) containing protease inhibitors (Roche) and lysed in 1 ml of 1% SDS, 10 mM EDTA, 50 mM Tris--HCl (pH 8.1) plus protease inhibitors. Sonication was carried out to produce fragments of 1 kb or under.

Immunoprecipitations were performed overnight at 4°C with 10 μl of a CTCF-specific antibody (Upstate 07-729) and 200 μl of chromatin (corresponding to 1 × 10^7^ cells), and complexes were collected with protein A agarose beads for 1 h. No antibody samples were prepared, in which chromatin was incubated with protein A agarose beads alone. Immunoprecipitations were washed, DNA eluted and cross-links reversed according to the Upstate protocol.

All immunoprecipitations were performed in duplicate or triplicate. Immunoprecipitated and 1/10 diluted input DNA samples were used as templates for Taqman qPCR. Primer and probes sets corresponding to regions of interest within the *CFTR* locus were designed using primer express 1.0 software ([Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1)) and obtained from Eurogentec or IDT. Reactions were carried out following the ABI protocol and performed in triplicate.

Enhancer-blocking activity assay
--------------------------------

The plasmids pNI and pNI-FII were a kind gift from the Felsenfeld group ([@B27]). Enhancer-blocking assays were performed as previously described ([@B27],[@B28]). G418-resistant colonies were counted after 2--3 weeks of selection and data subjected to statistical analysis by one-way ANOVA followed by Dunnett\'s multiple comparison test.

Electrophoretic mobility shift assays (EMSAs)
---------------------------------------------

Caco2 nuclear extracts were prepared by standard methods ([@B29]). *In vitro* translated (IVT) CTCF was made by *in vitro* transcription and translation of pCTCF ([@B30]) using the TNT-Kit (Promega) and following manufacturer\'s instructions. EMSA experiments were carried out as described previously ([@B6]). Antibody supershift reactions were performed using anti-CTCF (Upstate 07-729) or anti-RARα (sc-773×).

*In vitro* DNase I footprinting
-------------------------------

The +6.8 kb DHS was PCR-amplified using primers 6.8B-F (AAGAACATTATGAAAGGTGGTC; AC000061: 64235--64256) and 6.8B-R (AAGATAAAATGTCTTTGAGATT; AC000061: 64510--64489), and then cloned into pCRscript (Invitrogen). Following excision by either EcoRV/NotI or ClaI/SacII digestion, Klenow DNA polymerase fill-in with \[α-^32^P\]-dCTP was used to label either the sense or anti-sense strand, respectively. DNase I footprinting reactions were performed as described previously ([@B31]).

Chromosome conformation capture (3C)
------------------------------------

3C was performed as described previously ([@B32],[@B33]), with minor modifications. Briefly, 1 × 10^7^ cells were fixed with 2% formaldehyde for 10 min at room temperature. Cells were lysed in 5 ml cold lysis buffer \[10 mM Tris (pH 8), 10 mM NaCl, 0.2% NP-40, 1× protease inhibitor cocktail (Roche)\] and the nuclei collected by centrifugation. Following extraction with 0.3% SDS, chromatin was digested overnight with 2000 U HindIII. Ligations were performed in a total reaction volume of 6.5 ml, using 100 U T4 DNA ligase (Roche) and incubation at 14°C for 4 h followed by 30 min at room temperature. Cross-links were reversed by proteinase K treatment at 65°C overnight. Samples were purified by phenol--chloroform extraction followed by ethanol precipitation, and then re-suspended in 150 μl H~2~O. The concentration of each sample was determined by SYBR green qPCR, using the B13F/B13R primer set (amplicon found within a HindIII fragment; see [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1)) and comparison to a genomic DNA reference of known concentration. Samples were subsequently diluted to a concentration of 100 ng/μl.

A Taqman probe and reverse primer was designed that was specific to a HindIII fragment at the bait region of interest (i.e. the *CFTR* promoter). Multiple forward primers were then designed that were each specific to different HindIII fragments across the *CFTR* locus (see [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1) for primer and probe sequences and locations). Using a dilution series of digested/re-ligated BAC DNA template, each forward primer was demonstrated to function with the 'fixed' Taqman probe and reverse primer to amplify with 100% efficiency. To quantify ligation events within 3C samples, 200 ng of 3C template was used per 20 μl Taqman qPCR reaction. The ligation efficiency (or 'interaction frequency') between each fragment and the *CFTR* promoter was corrected for the interaction between two HindIII fragments within the ubiquitously expressed excision repair cross-complementing rodent repair deficiency, complementation group 3 *(ERCC3)* locus, which has been reported to adopt the same spatial conformation in different tissues ([@B16],[@B34],[@B35]).

RESULTS
=======

A cluster of four DHS was previously identified at the 3′-end of the *CFTR* gene, at +5.4 kb, + 6.8 kb, +7.0 kb and +7.4 kb from the *CFTR* translation termination site ([@B13]). The DHS at +5.4 kb and +7.0 kb were observed in a variety of cell types, irrespective of *CFTR* expression; however, the DHS at +6.8 kb and +7.4 kb were only found in a restricted number of *CFTR*-expressing cell-types, including primary human epididymis cells.

A predicted CTCF-binding site within the +6.8 kb DHS corresponds to a 60-bp DNase I footprint
---------------------------------------------------------------------------------------------

An *in silico* search for regulatory factors that could bind to the +5.4 kb, +6.8 kb, +7.0 kb and +7.4 kb DHS regions of the *CFTR* locus (AC000061 62735--65135), revealed a site within the +6.8 kb DHS region that matched the consensus sequence for CTCF binding ([@B7],[@B30]) at 13 out of 14 bp (AC000061 64412--64399) ([Table 1](#T1){ref-type="table"}). Table 1.Potential CTCF-binding site within the +6.8 kb DHS region![](gkn1056i1.jpg)[^1]

A 275-bp fragment spanning the +6.8 kb DHS (AC000061 64235--64510) was labelled at the 3′-end of either the sense or the anti-sense strand and used as a template for DNase I footprinting. In the presence of Caco2 cell nuclear extract, the +6.8 kb DHS sense strand exhibited protection from DNase I digestion (PR1) over 60 bp, at AC000061 64373--64436 ([Figure 1](#F1){ref-type="fig"}A and [Supplementary Figure 1](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1)). A weaker protected region was also evident at the corresponding location on +6.8 kb DHS anti-sense strand ([Figure 1](#F1){ref-type="fig"}B). Extensive DNase I footprints are characteristic of those produced by CTCF binding ([@B36]), and furthermore, the putative site of interaction with CTCF identified *in silico* was centrally positioned within PR1 ([Figure 1](#F1){ref-type="fig"}). Figure 1.*In vitro* DNase I footprinting of the +6.8 kb DHS probe. Experiments using (**A**) sense and (**B**) anti-sense strands are shown. Both gel images are labelled as follows: 1, AG ladder; 2, No DNase I; 3, No Caco2 nuclear extract; 4 and 5, 40 μg and 80 μg Caco2 cell nuclear extract, respectively. For both panels, protected region 1 (PR1) is highlighted by a bold vertical line. Narrow vertical line marked with an asterisk shows position of putative CTCF-binding site.

CTCF binds to the +6.8 kb DHS sequence *in vitro*
-------------------------------------------------

*In vitro* binding of CTCF at the putative +6.8 kb DHS-binding site (PR1), was investigated by EMSA. A 78-bp oligonucleotide probe, DHS6.8^oligo^, was generated that spanned the putative +6.8 kb DHS CTCF-binding site ([Figure 2](#F2){ref-type="fig"}A and [Supplementary Figure 1](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1)). DHS6.8mut^oligo^, had the same sequence with the exception of alterations in the 14-bp putative CTCF-binding site core which was positioned centrally within DHS6.8^oligo^ ([Figure 2](#F2){ref-type="fig"}A). EMSA experiments with the DHS6.8^oligo^ probe demonstrated that this sequence binds IVT CTCF ([Figure 2](#F2){ref-type="fig"}B, i) and that the complex formed was supershifted with an antibody specific to CTCF ([Figure 2](#F2){ref-type="fig"}B, ii), but not an isotype control antibody (anti-RARα). DHS6.8^oligo^ also formed a complex with Caco2 nuclear extract that was of the same mobility as that formed with IVT CTCF ([Figure 2](#F2){ref-type="fig"}C, i). The complex formed between DHS6.8^oligo^ and Caco2 nuclear extract was competed by unlabelled self, but not by DHS6.8mut^oligo^ ([Figure 2](#F2){ref-type="fig"}C). The complex was also competed by FII (a known CTCF-binding site from the chicken *β-globin* locus), but not by a mutant version of this probe (FII mut) ([Figure 2](#F2){ref-type="fig"}C). Furthermore, the complex formed between DHS6.8^oligo^ and Caco2 nuclear extract was also supershifted by an antibody specific to CTCF ([Figure 2](#F2){ref-type="fig"}D, ii), but not by an isotype control antibody. When the DHS6.8mut^oligo^ probe was used in EMSA experiments, the CTCF complex was not observed with either Caco2 nuclear extract ([Figure 2](#F2){ref-type="fig"}E) or IVT CTCF (data not shown). In the presence of Caco2 nuclear extract, DHSmut^oligo^ exhibited two weak complexes (\*), possibly due to CTCF site mutation creating novel transcription factor binding sites. However, given the lack of interaction between DHS6.8mut^oligo^ and IVT CTCF, these novel complexes are likely to involve proteins other than CTCF. Figure 2.*In vitro* binding of CTCF at the +6.8 kb DHS region. (**A**) The DHS6.8^oligo^ and DHS6.8mut^oligo^ probes. The putative CTCF-binding site core is highlighted. Oligonucleotides were designed to form BssHII sticky ends when annealed (shown in italics), facilitating cloning into the AscI site of pNI. Mutated bases in DHS6.8mut^oligo^ are underlined. (**B**) IVT CTCF; (**C**, **D**), Caco2 nuclear extracts. (B) EMSA using DHS6.8^oligo^. Supershift was performed with an anti-CTCF antibody and anti-RAR *β* was used as isotype control. (C) EMSA with DHS6.8^oligo^. Competition reactions were performed with 100× excess of unlabelled DHS6.8^oligo^ (self), DHS6.8mut^oligo^ (self mut), FII (known CTCF-binding site from chicken *β-globin* locus) and mutant (FIImut). (D) EMSA with DHS6.8^oligo^. Supershift reactions were performed as in (B). (**E**) EMSA with DHS6.8mut^oligo^. Complex marked i represents CTCF in complex with DHS6.8^oligo^ and ii the antibody-supershifted CTCF complex. Undefined interactions formed between 6.8mut^oligo^ and Caco2 nuclear extract are marked by \*.

These data conclusively demonstrate a strong *in vitro* interaction between the +6.8 kb DHS region and CTCF.

CTCF binds to the +6.8 kb DHS *in vivo*
---------------------------------------

Since CTCF showed a strong interaction with DHS6.8^oligo^ *in vitro*, ChIP with an antibody specific for CTCF followed by Taqman quantitative PCR analysis was used to investigate *in vivo* binding at this site. Chromatin from two cell types was evaluated: Caco2 colon carcinoma cells and fetal male primary epididymis cells, both of which express abundant *CFTR*. For Caco2 chromatin, ChIP with an antibody specific to CTCF gave an ∼5-fold enrichment of the +6.8 kb DHS relative to a region within *CFTR* intron 17a where there is no predicted CTCF-binding site ([Figure 3](#F3){ref-type="fig"}A). The +15.6 kb DHS of *CFTR* (located ∼9 kb 3′ to the +6.8 kb DHS), that was previously demonstrated to possess CTCF-independent enhancer-blocking activity, showed no CTCF-specific enrichment, consistent with our earlier work ([@B6]). In contrast, using primary epididymis chromatin, the CTCF-specific antibody enriched the +6.8 kb DHS region by about 15-fold relative to *CFTR* intron 17a ([Figure 3](#F3){ref-type="fig"}B). Approximately 2.5 kb either side of the +6.8 kb DHS, at +4.4 kb and +9.3 kb relative to the *CFTR* translation end-point, CTCF-specific enrichment in primary epididymis cells returned to baseline levels. The +15.6 kb DHS again showed no CTCF-specific enrichment in epididymis chromatin. For both Caco2 and primary epididymis chromatin, negative control ChIP experiments in which chromatin was immunoprecipitated with protein A beads alone (no antibody) resulted in baseline levels of enrichment at all regions (data not shown). Taken together, these results demonstrate strong *in vivo* binding of CTCF at the +6.8 kb DHS in primary epididymis cells, with a much lesser interaction between CTCF and the +6.8 kb DHS in the Caco2 cell line. It is noteworthy that CTCF-specific enrichment of the +6.8 kb DHS in primary epididymis cells correlates with the presence of the +6.8 kb DHS in this cell type ([@B13]). Figure 3.*In vivo* binding of CTCF at the +6.8 kb DHS region. Immunoprecipitations were performed with a CTCF-specific antibody and chromatin from (**A**) Caco2 cells and (**B**) Primary epididymis cells. No antibody control samples were also prepared, in which chromatin was incubated with Protein A agarose beads alone (data not shown). Samples were subjected to Taqman quantitative PCR analysis using probes specific for intron 17a and regions of interest 3′ to *CFTR*. CTCF-specific enrichment of each of these regions is shown relative to levels at intron 17a (which contains no predicted CTCF-binding sites). Vertical dashed line represents location of CFTR translation end-point, and *x*-axis on the right of this is drawn to scale (i.e. each data point accurately reflects the relative positions of Taqman amplicons). Immunoprecipitations were repeated at least twice. PCRs were performed in triplicate and Ct values averaged. Error bars denote S.E.M.

In addition to the CTCF-binding site that we determined experimentally at the +6.8 kb DHS, another CTCF-binding site was predicted *in silico* at the 3′-end of the *CFTR* locus, ([@B7]). This site is located at +2.9 kb from the *CFTR* translation end-point (AC000061:60371--60384) and has a 12 out of 14-bp match with the CTCF consensus. To evaluate CTCF-specific enrichment of this region in Caco2 and primary epididymis cells, an additional Taqman primer/probe set was designed. Both Caco2 and primary epididymis cells showed only modest CTCF-specific enrichment of the +2.9 kb region (∼4- and 5-fold, respectively) ([Figure 3](#F3){ref-type="fig"}A and B) in comparison to 15-fold enrichment at the +6.8 kb site in epididymis chromatin. Moreover, the lack of any known DHS at this region in these cell types brings into question the biological significance of the +2.9 kb predicted CTCF-binding site.

Enhancer-blocking activity at the +6.8 kb DHS
---------------------------------------------

Binding of CTCF is necessary for enhancer-blocking activity at the majority of vertebrate insulator elements ([@B37],[@B38]). Since the +6.8 kb DHS binds CTCF, and is located in an intergenic region, we used a well-established assay ([@B27],[@B28]) to investigate whether this element possessed enhancer-blocking activity. This test uses the pNI plasmid, in which the mouse HS2 enhancer of the *β-globin* LCR is positioned upstream of a *neo^r^* gene driven by the human γ-*globin* promoter. Sequences to be assayed for insulator activity are cloned into a unique AscI site located between the enhancer and promoter. Transfection of these constructs into K562 human erythroleukemia cells yields G418-resistant colonies, with a frequency dependent on the level of enhancer-promoter communication (and hence enhancer-blocking activity of the intervening fragment).

The DHS6.8^oligo^ and DHS6.8mut^oligo^ oligonucleotides were designed with BssHII sticky ends ([Figure 2](#F2){ref-type="fig"}A), facilitating their direct cloning into the AscI site of pNI. An enhancer-blocking activity assay was performed, with the number of neomycin-resistant colonies obtained for each construct normalized to the empty pNI plasmid. Results were subjected to statistical analysis by one-way ANOVA followed by Dunnett\'s multiple comparison test. When inserted into the enhancer-blocking position of pNI, FII, the CTCF-binding core from the known 5′HS4 chicken *β-globin* insulator ([@B28],[@B37]), significantly reduced the number of colonies (2- to 3-fold; *P* \< 0.01) ([Figure 4](#F4){ref-type="fig"}). The pNI-DHS6.8^oligo^ construct also gave a significantly lower number of colonies compared to pNI (2- to 3-fold, *P* \< 0.01). In contrast, although the pNI-DHS6.8mut^oligo^ construct gave a slightly lower number of colonies than pNI, this was not significant (*P* \> 0.05). This suggests that CTCF binding at the +6.8 kb DHS is responsible, at least in part, for the enhancer-blocking activity of this element. Figure 4.Enhancer-blocking activity at the +6.8 kb DHS region. Each construct used in the enhancer-blocking assay is depicted as follows: pNI is the empty pNI plasmid and pNI-FII (FII) contains a known insulator from the chicken *β-globin* locus (represented by a triangle). pNI-6.8 (6.8) contains the wild-type DHS6.8^oligo^ (represented by a rectangle) and pNI-6.8mut (6.8mut) contains the mutant version DHS6.8mut^oligo^ (represented by a rectangle with a cross in it). pNI-6.8NdeI (6.8NdeI) contains the wild-type DHS6.8^oligo^ sequence cloned upstream of the HS2 enhancer (as opposed to between HS2 and the *γ-neo* reporter). The number of Neo^R^ colonies obtained for empty pNI was given a value of 1, and the number of colonies obtained with all other constructs was expressed relative to this value. Error bars denote S.E.M. of triplicate experiments carried out on three separate occasions, except for 6.8NdeI which was performed in triplicate on one occasion. Different plasmid DNA preparations were used for each experiment within the triplicates. ^\*\*^*P* \< 0.01.

As some CTCF-binding sites are associated with silencer activity ([@B39]), we investigated this possibility for the *CFTR* +6.8 kb DHS CTCF-binding site. A modified version of DHS6.8^oligo^ was generated with NdeI sticky ends (as opposed to BssHII), enabling DHS6.8^oligo^ to be cloned into an NdeI site upstream of the HS2 enhancer (as shown in [Figure 4](#F4){ref-type="fig"}). However, in this arrangement, DHS6.8^oligo^ had no significant effect upon colony number (*P* \> 0.05) (see 6.8NdeI, [Figure 4](#F4){ref-type="fig"}). This demonstrates that the enhancer-blocking activity of the *CFTR* +6.8 kb DHS is directional (in that it only has an effect when positioned between an enhancer and promoter), consistent with this element being an insulator rather than a silencer ([@B27]).

Looping of the *CFTR* locus in *CFTR*-expressing cell types
-----------------------------------------------------------

CTCF sites that flank the *β-globin* locus interact with the promoters of actively expressed globin genes, bringing them within proximity of the *β-globin* 'active chromatin hub' (ACH) ([@B16; @B17; @B18]). Within the *CFTR* locus, in addition to the 3′ CTCF-binding site at +6.8 kb investigated here, we previously characterized a CTCF-binding site 5′ to the locus in the −20.9 kb DHS region ([@B6]). The presence of these two DHS flanking the locus suggested similarities to *β-globin*. Hence we investigated whether either of the CTCF sites that flank *CFTR* interacts with the *CFTR* promoter region using chromosome conformation capture (3C) ([@B33]).

Formaldehyde-crosslinked nuclei from human primary skin fibroblasts (*CFTR* non-expressing) and human primary epididymis epithelial cells (*CFTR*-expressing) were subjected to HindIII digestion and subsequent 3C analysis. A fixed Taqman probe and reverse primer were designed within a HindIII fragment at the *CFTR* promoter, and multiple forward primers were generated within distal regions across the *CFTR* locus ([Figure 5](#F5){ref-type="fig"}A and [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkn1056/DC1)). These forward primers were located within HindIII fragments encompassing the −20.9 kb, +6.8 kb and +15.6 kb DHS, and within specific intronic HindIII fragments. The assay fragments were positioned ∼25 to 50 kb apart, such that they would give a good overall representation of the structure of the *CFTR* locus ([Figure 5](#F5){ref-type="fig"}A). Real-time PCR reactions using the 'fixed' reverse probe/primer and each of the 'variable' forward primers enabled quantification of ligation events (subsequently referred to as 'interaction frequency') between the *CFTR* promoter and specific distal regions within each 3C sample. Figure 5.3C analysis of the *CFTR* locus. (**A**) Scale figure of the *CFTR* gene with exons marked by vertical bars and the translation start site represented by a bent arrow. Small vertical lines above the gene denote HindIII sites and half arrow heads show the locations of 3C primers. Due to space constraints, primers are not drawn to scale, and the fixed *CFTR* promoter HindIII fragment is expanded, showing the location of Taqman probe (joined ball and star) and the reverse primer. The --20.9 kb DHS and +6.8 kb DHS locations are also indicated. (**B**) 3C data from primary human skin fibroblast cells. (**C**) 3C data from primary human epididymis cells. The *x*-axis for each chart is drawn to scale, with units representing base pairs relative to the *CFTR* translation start point (0). Both charts are aligned with the *CFTR* gene figure above. Vertical dashed lines represent HindIII sites. The interaction frequency between a fixed HindIII fragment at the *CFTR* promoter (shaded grey) and HindIII fragments at various regions across the *CFTR* gene was measured by Taqman quantitative PCR. The interaction frequency at each point is expressed relative to the interaction between two HindIII fragments within the ubiquitously expressed *ERCC3* gene. Data shown represent the average of two independent experiments. Each real-time PCR reaction was performed three times and averaged. Error bars denote SEM.

Within primary human skin fibroblasts, which do not express *CFTR*, interaction frequency with the *CFTR* promoter decreased as a function of distance from the promoter, with no significant interaction between the *CFTR* promoter and either the −20.9 kb or +6.8 kb DHS ([Figure 5](#F5){ref-type="fig"}B). Furthermore, there were no peaks of interaction at any of the intronic locations assayed. These data suggest that within *CFTR*-negative primary skin fibroblasts, the *CFTR* locus exists in a relaxed structure, or at least one that does not contain stable loops that bring distal regulatory elements close to the promoter.

In contrast to the skin fibroblast data, in *CFTR*-expressing primary epididymis cells, the *CFTR* locus exhibited a 3C profile that suggested specific interactions between the promoter and distal regions ([Figure 5](#F5){ref-type="fig"}C). For example, a moderate interaction was detected between the *CFTR* promoter and a region within intron 19, possibly indicating the presence of an intronic regulatory element that interacts with the promoter. However, most significantly, a strong interaction frequency was detected between the *CFTR* promoter region and a HindIII site at the 3′-end of the *CFTR* locus encompassing the +6.8 kb DHS. Indeed, despite being located more than 200 kb from the *CFTR* promoter region, this 3′ fragment demonstrated an interaction frequency with the *CFTR* promoter that was greater than a HindIII fragment within intron 1 of the *CFTR*, \<10 kb from the *CFTR* promoter ([Figure 5](#F5){ref-type="fig"}C). For the adjacent 3′ fragment (∼210 kb from the *CFTR* promoter), interaction frequency fell dramatically to an apparently baseline level, suggesting that the *CFTR* promoter interacts specifically with elements in the HindIII fragment encompassing the +6.8 kb DHS.

Unlike the +6.8 kb DHS, in primary epididymis cells, no significant interaction was detected between the *CFTR* promoter and the −20.9 kb DHS CTCF-binding site ([Figure 5](#F5){ref-type="fig"}C). The lack of interaction between these two sites was also confirmed using a −20.9 kb DHS-specific Taqman probe and reverse primer in combination with a forwards primer specific to the *CFTR* promoter region (data not shown). Furthermore, using the −20.9 kb DHS probe, no interaction was detected with the +6.8 kb DHS.

These data indicate that within *CFTR*-expressing primary epididymis cells, the *CFTR* locus exists within a looped structure, with a HindIII fragment encompassing the +6.8 kb DHS CTCF site being in close proximity to the *CFTR* promoter. In contrast, at the opposite end of the locus, no interaction is apparent between the −20.9 kb DHS CTCF site and the *CFTR* promoter.

DISCUSSION
==========

Expression of the *CFTR* gene is tightly controlled, both temporally during development and spatially in different tissue types. However, the underlying genetic mechanisms responsible for conferring these complex *CFTR* expression patterns are poorly understood. The *CFTR* promoter is weak and demonstrates little tissue specificity, suggesting that key regulatory elements must be located elsewhere within the gene or in adjacent genomic regions. To identify potential regulatory elements, we previously performed DHS mapping in a variety of cell types, across 400 kb spanning the *CFTR* locus. Of the DHS that were found, a subset showed some correlation with *CFTR* expression. These included two DHS at the 3′-end of the gene, at +6.8 kb and +7.4 kb from the *CFTR* translation end-point.

The +6.8 kb DHS was only observed in fetal epididymis cells and adult lung tissue, both *CFTR*-expressing primary cell types. Here we demonstrate that the +6.8 kb DHS contains a predicted CTCF-binding site with a close match to the consensus. Moreover, this region shows a strong *in vivo* association with CTCF in chromatin extracted from primary epididymis cells, correlating with the presence of the DHS in these cells. Although we did not previously observe the +6.8 kb DHS in Caco2 colon carcinoma cells experiments with Caco2 chromatin showed slight CTCF-specific enrichment at this site. It is thus possible that within a large population of Caco2 cells, a small number of cells exhibit the +6.8 kb DHS.

While most CTCF-binding sites throughout the human genome appear to be cell-type invariant, a fraction are cell-type specific ([@B7]). This cell-type specificity may be conferred by DNA methylation at CpG dinucleotides, an epigenetic mark that is known to affect CTCF binding ([@B38],[@B40]). However, within the *CFTR* +6.8 kb DHS, there is an absence of CpG dinucleotides, with the nearest CpG located about 200 bp 5′ to the CTCF-binding site core. It therefore seems unlikely that tissue-specific control of CTCF binding at the +6.8 kb DHS is controlled by DNA methylation, suggesting the use of a different regulatory mechanism. For example, it is possible that events leading to the formation of the +6.8 kb DHS, such as nucleosome remodelling, may regulate CTCF binding.

Genome-wide analysis of CTCF binding in primary human fibroblast IMR90 cells revealed ∼14 000 genomic regions flanked by CTCF-binding sites, so-called CTCF-pair-defined domains (CPDs) ([@B7]). Within these CPDs, the average distance between CTCF-binding sites was found to be 212 090 bp. It is therefore of interest that the *CFTR* gene is contained within an apparent CPD of 214 000 bp, considering the distance between the +6.8 kb DHS and the previously described −20.9 kb DHS CTCF-dependent insulator element ([@B6]).

At the *β-globin* locus, CTCF sites that flank the locus associate with actively transcribed globin promoters within the *β-globin* active chromatin hub (ACH) ([@B16; @B17; @B18]). In the present study, we demonstrated that there is no association between the *CFTR* promoter and the −20.9 kb DHS CTCF-binding element in the upstream flanking region, irrespective of *CFTR* expression. In contrast, in *CFTR*-expressing primary epididymis cells, we observed a strong interaction between the *CFTR* promoter and a region at the 3′-end of the *CFTR* gene encompassing the +6.8 kb DHS CTCF-binding site. This interaction was not seen in skin fibroblast cells, which do not express *CFTR*, suggesting that 'looping' of the *CFTR* locus correlates with active expression of the gene.

In addition to the +6.8 kb DHS, the 3′ HindIII fragment demonstrated here to interact with the *CFTR* promoter encompasses a number of other DHS. These include the cluster of adjacent DHS (+5.4 kb, +7.0 kb and +7.4 kb) ([@B13]) and the previously characterized +15.6 kb DHS enhancer-blocking element ([@B6]). Within primary epididymis cells, the +6.8 kb, +7.0 kb and +15.6 kb DHS were all evident ([@B13]). We therefore cannot rule out the possibility that looping of the *CFTR* locus in primary epididymis cells is induced by interaction of either the +7.0 kb or the +15.6 kb DHS with the *CFTR* promoter. However, given that in other cell types the presence of these DHS shows poor correlation with *CFTR* expression, it seems highly likely that an important role is performed by the +6.8 kb DHS, which was only observed in a subset of *CFTR*-expressing primary cell types.

It seems probable that the induction and maintenance of looping of the *CFTR* locus is dependent on the interaction of multiple regulatory elements located in different DHS regions, both intronic and flanking the gene ([Figure 6](#F6){ref-type="fig"}). Indeed we now have evidence that several intronic DHS also contribute to the loops (Ott *et al.*, 2008. Journal of Cellular and Molecular Medicine, in Press). Hence, though a single element, such as that within the DHS at the 3′-end of the gene is unlikely to be solely responsible for the looping phenomenon, it may play a pivotal role in primary epididymis. We predict a co-ordinated interplay of the regulatory elements located within DHS at the 3′-end of the *CFTR* gene and note similarities between this cluster of DHS and the human *β*-*globin* locus control region (LCR) (41): (i) Both comprise five DHS (+5.4 kb, +6.8 kb, +7.0 kb, +7.4 kb and +15.6 kb in the case of *CFTR*; 5′HS1-5 in the case of *β-globin*). In the case of the *CFTR* 3′ region, these DHS are spread over 11 kb, while the *β-globin* LCR is about 16 kb in size; (ii) both contain CTCF-binding elements (+6.8 kb DHS in the case of *CFTR*; 5′HS5 in the case of *β-globin*); (iii) when their corresponding genes are actively transcribed, both regions contain peaks of euchromatin-specific histone modifications (at the +15.6 kb DHS in the case of *CFTR*) ([@B6]); and (iv) both interact with the promoters of their corresponding genes, inducing genomic loops and the formation of an ACH. Future experiments will determine whether the DHS cluster 3′ to *CFTR* does indeed represent an LCR. Understanding the precise mechanisms by which *CFTR* expression is regulated is likely to be of direct practical relevance in the design of effective gene therapy vectors for cystic fibrosis. Figure 6.Looping model for *CFTR* gene. In *CFTR*-expressing cell types, such as primary epididymis cells, elements in the *CFTR* 3\' flanking region are in close proximity with the *CFTR* promoter. This 3\' flanking region includes the tissue-specific +6.8-kb DHS, shown here to bind CTCF, as well as other previously described DHS ([@B13],[@B6]). Protein factors bound at each of these sites interact with the promoter-bound transcription machinery, thus forming an active chromatin hub (ACH) and helping regulate expression of the *CFTR* gene. In addition to DHS from the 3\' flanking region, intronic DHS such as the intestine-specific intron 1 element ([@B31],[@B42],[@B43]) and others (represented by the elements marked '?'), may contribute to the CFTR ACH in a tissue-specific manner.
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[^1]: The CTCF consensus ([@B7],[@B30]) is shown at the top of the table followed by the putative binding site within the +6.8 kb DHS. Bases shaded in grey indicate matches to the consensus.
